Levodopa pharmacokinetics and dyskinesia: Are there sex-related differences?

Neurological Sciences

Volumn 24, Issue 3, 2003, Pages 192-193

  Martinelli, P ^a   Contin, M ^a   Scaglione, C ^a   Riva, R ^a   Albani, F ^a   Baruzzi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; SEX DIFFERENCE; STANDARD; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEXUAL DEVELOPMENT; STATISTICAL MODEL;

AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BENSERAZIDE; CASE-CONTROL STUDIES; DYSKINESIAS; FEMALE; HALF-LIFE; HUMANS; LEVODOPA; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PARKINSON DISEASE; SEX CHARACTERISTICS;

EID: 0142217536     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-003-0125-z     Document Type: Article

References (8)

1. Marsden CD (1994) Parkinson's disease. J Neurol Neurosurg Psychiatry 57:672-681
2. Parkinson Study Group (1989) DATATOP: a multicenter controlled trial in early Parkinson's disease. Arch Neurol 46:1052-1060
3. Zappia M, Crescibene L, Arabia G et al (2002) Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 2:79-82
4. Contin M, Riva R, Martinelli P et al (2001) Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther Drug Monit 23:621-629
5. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752
6. Contin M, Riva R, Martinelli P et al (1991) Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 41:463-466
7. Kompoliti K, Adler CH, Raman MS et al (2002) Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58:1418-1422
8. Boudikova B, Szumlanski C, Maidak B et al (1990) Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48:381-389